An increase in amoxicillin induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris-RCPVs) and better describe this rare adverse drug reaction. Forty-five AICN cases were identified between 1985 and 2016. All cases, except one, were reported since 2010. Amoxicillin (AMX) was administered intravenously (65 [43;110] mg/kg/day) in all patients, either for treating infection (n=15) or as surgical prophylaxis (n=30). Delay between AMX administration and AICN onset was 1 [1; 3] day; 30, 4 and 11 patients developed KDIGO stage 1,2 and 3, acute kidney injury, respectively. Delay between AICN onset and kidney function recovery was 4 [2; 6] days. Precipitating factors were identified in only one third of cases. Twelve patients required ICU admission, and 8, renal replacement therapy. Neither chronic kidney disease nor death was observed. We confirmed the recent and dramatic increase of AICN to the Paris-RCPVs since 2010. The absence of precipitating factors in the majority of cases and the onset of AICN in apparent routine indications, such as surgical prophylaxis, are alarming and justify a high vigilance from all AMX prescribers.
http://ift.tt/2kTmkvL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου